Skip to main
CRVO
CRVO logo

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed Inc. demonstrates a robust financial position with cash, cash equivalents, and marketable securities amounting to $38.9 million, indicating operational sustainability into mid-2026. The positive clinical data from the 16-week extension of the RewinD-LB Phase 2b trial for neflamapimod, which showcased statistically significant improvements in synaptic dysfunction symptoms, underlines the therapeutic potential of the company's lead candidate in treating age-related neurologic disorders. Additionally, the increase in R&D expenses reflects a committed investment in advancing clinical trials, strategically positioning CervoMed for future growth and development in the biotechnology sector.

Bears say

CervoMed Inc. faces significant financial risks due to its status as a clinical-stage biotechnology company with no current revenue-generating products and a history of operating losses since its inception. The company is subject to fierce market competition, which may hinder its ability to penetrate the market effectively or maintain suitable pricing for its product candidate, Neflamapimod. Additionally, delays in clinical development, regulatory approvals, and commercialization efforts could lead to increased costs and extended timelines, further complicating the company’s financial stability and growth prospects.

CervoMed Inc (CRVO) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 5 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Sep 11, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.